Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.
Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart - Tonghua Dongbao Pharmaceutical - occupied merely 3.4% or so.
http://www.digitaljournal.com/pr/1508568
Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart - Tonghua Dongbao Pharmaceutical - occupied merely 3.4% or so.
http://www.digitaljournal.com/pr/1508568